Recurrent Multiple Myeloma Clinical Trials in Buffalo, New York
2 recruitingBuffalo, New York
Showing 1–2 of 2 trials
Recruiting
Phase 1
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Roswell Park Cancer Institute15 enrolled1 locationNCT06622005
Recruiting
Phase 2
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Refractory Multiple MyelomaRecurrent Multiple MyelomaExtramedullary Disease in Multiple Myeloma
Roswell Park Cancer Institute28 enrolled1 locationNCT06627751